Meridian Bioscience is a life science company with principal businesses in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, Polymerase Chain Reaction master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. Co.'s reportable segments are: Diagnostics, which includes diagnostic tests and transport media; and Life Science. The VIVO stock yearly return is shown above.
The yearly return on the VIVO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VIVO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|